Is the prevalence of CYP2C19 genetic variants different in Pacific people than in New Zealand Europeans?
Nuala Helsby, Michael Goldthorpe, Peter Gow, Janak de Zoysa
There are large differences in how people respond to therapy: some people respond well, others have little or no benefit and some will have side effects. This inter-individual variability may be due to differences in how the body degrades drugs. Drugs are degraded in the body by liver enzymes such as cytochrome P450 (CYP). Many of the CYP enzymes display variability which can be predicted from a persons genotype (pharmacogenetics). For example, CYP2C19, an enzyme involved in the metabolism of more than 10% of the top 200 prescribed drugs, has genetic variants (CYP2C19*2 & CYP2C19*3) which result in a poor metabolism in certain people. Another variant (CYP2C19*17) has been associated with ultrarapid metabolism. These variants and their consequences have been extensively studied in European populations, but little is known about their presence in Pacific peoples. This study suggests that further work in this area is warranted.